VRTX stock forecast
Our latest prediction for Vertex Pharmaceuticals, Inc.'s stock price was made on the July 10, 2020 when the stock price was at 294.45$.
In the short term (2weeks), VRTX's stock price should underperform the market by -1.00%. During that period the price should oscillate between -6.16% and +4.24%.
In the medium term (3months), VRTX's stock price should underperform the market by -3.37%. During that period the price should oscillate between -18.89% and +11.40%.Get email alerts
Create a solid portfolio with VRTX
About Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
At the moment the company generates 4819M USD in revenues.
On its last earning announcement, the company reported a profit of 5.77$ per share.
The book value per share is 10.51$
Three months stock forecastJuly 10, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|